Jules Bordet Institute

GE HealthCare leads Thera4Care, a €25.3 million initiative to revolutionize theranostics in Europe, aiming to broaden patient access to personalized cancer treatments by standardizing and scaling the production and use of key isotopes and integrating AI for better diagnostics and therapy.

BRACELET-1 study results show improved overall survival (OS) and progression-free survival (PFS) when combining pelareorep with paclitaxel for HR-positive, HER2-negative advanced or metastatic breast cancer patients. The median OS was not reached with pelareorep/paclitaxel vs 18.2 months with paclitaxel alone, and the median PFS was 12.1 months vs 6.4 months. The overall response rate (ORR) was 37.5% with pelareorep/paclitaxel vs 13.3% with paclitaxel alone. These findings support further development of pelareorep in clinical settings.